- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Corium Submits Application for Alzheimer’s Treatment in Patch Formulation
The company has received a PDUFA action date of March 11, 2022, for Adlarity, a transdermal patch for the treatment of Alzheimer’s disease.
Corium has submitted a new drug application for once-weekly Adlarity (donepezil transdermal system), a patch formulation of donepezil for the treatment of patients with dementia due to mild, moderate, or severe Alzheimer's disease. Corium is seeking approval of two transdermal doses capable of delivering 5 or 10 milligrams of donepezil daily.
This submission is the second one for Adlarity. The company has previously received a complete response letter in July 2020. The current submission contains data from three clinical trials that were conducted in response to that FDA letter.
Adlarity uses the company Corplex technology, which enables transdermal therapeutics that incorporate small molecule drugs to be delivered through the skin. The Adlarity transdermal patch is worn for seven days.
Adlarity contains donepezil, the active ingredient in Pfizer’s/Eisai’s Aricept, which was first launched in 1996, and generics began to be launched in 2011. Corium officials said the transdermal patch aims to avoid the side effects associated with gastrointestinal tract absorption, such as ulcers.
Corium also is developing the Corplex technology for the delivery of drugs to treat patients with other CNS conditions.
If approved, Adlarity would be Corium’s second CNS product approved for the U.S. market in 12 months. In July 2021, Corium commercially launched Azstarys in the United States for the treatment of attention deficient hyperactivity disorder in patients 6 years of age and older, following FDA approval in March 2021.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
